The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial
暂无分享，去创建一个
E. Montero | L. Aira | P. C. Rodríguez | C. Viada | Jorge A. Gómez | Patricia Hernández | M. Hernández | P. Hernández | I. Hernández | J. Gómez | D. Prada | Claudino Molinero | A. López | Y. Ávila | Y. Barrese | E. Moreno | A. Lopez | C. Molinero | J. P. Martínez | Y. Reyes | J. M. Milera | R. Torres | José P. Martínez | Dinorah Prada | Yusimí Reyes | María V. Hernandez | Ernesto Moreno | Joel M. Milera | Roberto Torres | Yinet Barrese